New and developing anesthesia drugs

References

• Sneyd JR, Rigby-Jones AE. New drugs and technologies, intravenous anaesthesia is on the move (again). Br J Anaesth. 2010;105:246–254.
   PubMed Web of Science ®Google Scholar
• Sneyd JR. Remimazolam: new beginnings or just a me-too? Anesth Analg. 2012;115:217–219.
   PubMed Web of Science ®Google Scholar
• Goudra BG, Singh PM. Remimazolam: the future of its sedative potential. Saudi J Anaesth. 2014;8:388–391.
   PubMedGoogle Scholar
• Wiltshire HR, Kilpatrick GJ, Tilbrook GS, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg. 2012;115:284–296.
   PubMed Web of Science ®Google Scholar
• Antonik LJ, Goldwater DR, Kilpatrick GJ, et al. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012;115:274–283.
   PubMed Web of Science ®Google Scholar
• Saari TI, Uusi-Oukari M, Ahonen J, et al. Enhancement of GABAergic activity: neuropharmacological effects of benzodiazepines and therapeutic use in anesthesiology. Pharmacol Rev. 2011;63:243–267.
   PubMed Web of Science ®Google Scholar
• Worthington MT, Antonik LJ, Goldwater DR, et al. A phase Ib, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Anesth Analg. 2013;117:1093–1100.
   PubMed Web of Science ®Google Scholar
• Rogers WK, McDowell TS. Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures. IDrugs. 2010;13:929–937.
   PubMed Web of Science ®Google Scholar
• Sato S, Doi M, Morita K, et al. Remimazolam a new ultra-short acting anesthetic shows similar efficacy and superior hemodynamic stability vs. propofol in general surgery patients with TIVA: results of a randomised, non-inferiority, phase IIb/III trial. Abstract Presentation, ASA Annual Meeting; 2015 Oct 28. p. A5018.
   Google Scholar
• Chahar P, Cummings KC. Liposomal bupivacaine: a review of a new bupivacaine formulation. J Pain Res. 2012;5:257–264.
   PubMedGoogle Scholar
• Hu D, Onel E, Singla N, et al. Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site. Clin Drug Investig. 2013;33:109–115.
   PubMed Web of Science ®Google Scholar
• Davidson EM, Barenholz Y, Cohen R, et al. High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. Anesth Analg. 2010;110:1018–1023.
   PubMed Web of Science ®Google Scholar
• Langford RM, Chappell GM, Karrasch JA, et al. A single administration of depobupivacaine intraoperatively results in prolonged detectable plasma bupivacaine and analgesia in patients undergoing inguinal hernia repair. Poster presented at: 62nd Annual Postgraduate Assembly of the New York State Society of Anesthesiologists; 2008 Dec 12–16; New York, NY.
   Google Scholar
• Dullenkopf A, Borgeat A. Local anesthetics. Differences and similarities in the “-cains”. Anaesthesist. 2003;52:329–340.
   PubMed Web of Science ®Google Scholar
• Covino BG. Pharmacology of local anaesthetic agents. Br J Anaesth. 1986;58:701–716.
   PubMed Web of Science ®Google Scholar
• Longhorn RK, Cross M. Bupivacaine toxicity. J Cardiothorac Vasc Anesth. 2000;14:759–760.
   PubMed Web of Science ®Google Scholar
• Bourne E, Wright C, Royse C. A review of local anesthetic cardiotoxicity and treatment with lipid emulsion. Local Reg Anesth. 2010;3:11–19.
   PubMedGoogle Scholar
• Viscusi ER, Sinatra R, Onel E, et al. The safety of liposome bupivacaine, a novel local analgesic formulation. Clin J Pain. 2014;30:102–110.
   PubMed Web of Science ®Google Scholar
• Gorfine SR, Onel E, Patou G, et al. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011;54:1552–1559.
   PubMed Web of Science ®Google Scholar
• Golf M, Daniels SE, Onel E. A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy. Adv Ther. 2011;28:776–788.
   PubMed Web of Science ®Google Scholar
• Haas E, Onel E, Miller H, et al. A double-blind, randomized, active-controlled study for post-hemorrhoidectomy pain management with liposome bupivacaine, a novel local analgesic formulation. Am Surg. 2012;78:574–581.
   PubMed Web of Science ®Google Scholar
• Smoot JD, Bergese SD, Onel E, et al. The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammoplasty: a randomized, double-blind, active-control study. Aesthet Surg J. 2012;32:69–76.
   PubMed Web of Science ®Google Scholar
• Cohen SM. Extended pain relief trial utilizing infiltration of Exparel(®), a long-acting multivesicular liposome formulation of bupivacaine: a Phase IV health economic trial in adult patients undergoing open colectomy. J Pain Res. 2012;5:567–572.
   PubMedGoogle Scholar
• Viscusi ER, Candiotti KA, Onel E, et al. The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers. Reg Anesth Pain Med. 2012;37:616–622.
   PubMed Web of Science ®Google Scholar
• Ilfeld BM, Viscusi ER, Hadzic A, et al. Safety and side effect profile of liposome bupivacaine (Exparel) in peripheral nerve blocks. Reg Anesth Pain Med. 2015;40:572–582.
   PubMed Web of Science ®Google Scholar
• Hamilton TW, Athanassoglou V, Trivella M, et al. Liposomal bupivacaine peripheral nerve block for the management of postoperative pain. Cochrane Database Syst Rev. 2016 Aug 25;(8). Art. No.: CD011476.
   PubMed Web of Science ®Google Scholar
• Tong YC, Kaye AD, Urman RD. Liposomal bupivacaine and clinical outcomes. Best Pract Res Clin Anaesthesiol. 2014;28:15–27.
   PubMedGoogle Scholar
• Dasta J, Ramamoorthy S, Patou G, et al. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012;28:1609–1615.
   PubMed Web of Science ®Google Scholar
• Craig RG, Hunter JM. Neuromuscular blocking drugs and their antagonists in patients with organ disease. Anaesthesia. 2009;64(Suppl 1):55–65.
   PubMed Web of Science ®Google Scholar
• Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg. 2007;104:575–581.
   PubMed Web of Science ®Google Scholar
• Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angewandte Chemie. 2002;41:266–270.
   Google Scholar
• Full prescribing information for Bridon (Sugammadex). Patheon Manufacturing Services LLC, Greenville, NC27834, USA for Merck Sharp & Dohme Corp, Merck & Co, Inc; 2015. [Revised 2016 Sep].
   Google Scholar
• Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005;103:695–703.
   PubMed Web of Science ®Google Scholar
• Keating GM. sugammadex: a review of neuromuscular blockade reversal. Drugs. 2016;76:1041–1052.
   PubMed Web of Science ®Google Scholar
• Hemmerling TM, Zaouter C, Geldner G, et al. Sugammadex: a short review and clinical recommendations for the cardiac anesthesiologist. Ann Card Anaesth. 2010;13:206–216.
   PubMedGoogle Scholar
• Staals LM, Snoeck MMJ, Driessen JJ, et al. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth. 2010;104:31–39.
   PubMed Web of Science ®Google Scholar
• Dahl V, Pendeville PE, Hollmann MW, et al. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009;26:874–884.
   PubMed Web of Science ®Google Scholar
• Cammu G, Coart D, De Graeve K, et al. Reversal of rocuroniuminduced neuromuscular block with sugammadex in heart failure patients: a prospective observational study. Acta Anaesthesiol Belg. 2012;63:69–73.
   PubMedGoogle Scholar
• de Kam PJ, van Kuijk J, Prohn M, et al. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study. Clin Drug Investig. 2010;30:599–611.
   PubMed Web of Science ®Google Scholar
• Zwiers A, van den Heuvel M, Smeets J, et al. Assessment of the potential for displacement interactions with sugammadex: a pharmacokinetic-pharmacodynamic modelling approach. Clin Drug Investig. 2011;31:101–111.
   PubMed Web of Science ®Google Scholar
• Abrishami A, Ho J, Wong J, et al. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. Anesth Analg. 2010;110:1239.
   PubMedGoogle Scholar
• de Kam PJ, Grobara P, Prohn M, et al. Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects. Int J Clin Pharmacol Ther. 2014;52:227–236.
   PubMed Web of Science ®Google Scholar
• Dirkmann D, Britten MW, Pauling H, et al. Anticoagulant effect of sugammadex: just an in vitro artifact. Anesthesiology. 2016;124:1277–1285.
   PubMed Web of Science ®Google Scholar
• de Kam P-J, El Galta R, Kruithof AC, et al. No clinically relevant interaction between sugammadex and aspirin on platelet aggregation and coagulation parameters. Int J Clin Pharmacol Ther. 2013;51:976–985.
   PubMed Web of Science ®Google Scholar
• de Kam P-J, Kruithof AC, van Lierop M-J, et al. Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects. Int J Clin Pharmacol Ther. 2014;52:631–641.
   PubMed Web of Science ®Google Scholar
• Rahe-Meyer N, Fennema H, Sam Schulman S, et al. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients. Anesthesiology. 2014;121:969–977.
   PubMed Web of Science ®Google Scholar
• Raft J, Betala Belinga JF, Jurkolow G, et al. Clinical evaluation of post-surgical bleeding after a sugammadex injection. Ann Fr Anesth Reanim. 2011;30:714–717.
   PubMedGoogle Scholar
• Tsur A, Kalansky A. Hypersensitivity associated with sugammadex administration: a systematic review. Anaesthesia. 2014;69:1251–1257.
   PubMed Web of Science ®Google Scholar
• Ho G, Clarke RC, Sadleir PH, et al. The first case report of anaphylaxis caused by the inclusion complex of rocuronium and sugammadex. A A Case Rep. 2016;7:190–192.
   PubMed Web of Science ®Google Scholar
• Del Valle EM. Cyclodextrins and their uses: a review. Process Biochem. 2004;39:1033–1046.
   Web of Science ®Google Scholar
• Mirakhur RK. Sugammadex in clinical practice. Anaesthesia. 2009;64(Suppl 1):45–54.
   PubMed Web of Science ®Google Scholar
• White PF, Tufanogullari B, Sacan O, et al. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex. Anesth Analg. 2009;108:846–851.
   PubMed Web of Science ®Google Scholar
• Lee C, Jahr JS, Candiotti K, et al. Reversal of profound rocuronium NMV with sugammadex is faster than recovery from succinylcholine. Anesthesiology. 2007;107:A988.
   Google Scholar
• Won YJ, Lim BG, Lee DK, et al. Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients: a systematic review and meta-analysis. Medicine (Baltimore). 2016;95:e4678.
   Google Scholar
• Abad-Gurumeta A, Ripolles-Melchor J, Casans-Frances R, et al. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia. 2015;70:1441–1452.
   PubMed Web of Science ®Google Scholar
• Sacan O, White PF, Tufanogullari B, et al. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg. 2007;104:569–574.
   PubMed Web of Science ®Google Scholar
• Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. Br J Anaesth. 2015;115:743–751.
   PubMed Web of Science ®Google Scholar
• Haerter F, Simons JCP, Foerster U, et al. Comparative effectiveness of calabadion and sugammadex to reverse non-depolarizing neuromuscular-blocking agents. Anesthesiology. 2015;123:1337–1349.
   PubMed Web of Science ®Google Scholar
• Hoffmann U, Grosse-Sundrup M, Eikermann-Haerter K, et al. Calabadion: a new agent to reverse the effects of benzylisoquinoline and steroidal neuromuscular-blocking agents. Anesthesiology. 2013;119:317–325.
   PubMed Web of Science ®Google Scholar
• Diaz-Gil D, Haerter F, Falcinelli S, et al. A novel strategy to reverse general anesthesia by scavenging with the acyclic Cucurbit[n]uril-type molecular container calabadion 2. Anesthesiology. 2016;125:333–345.
   PubMed Web of Science ®Google Scholar
• Heerdt PM, Sunaga H, Owen JS, et al. Dose-response and cardiopulmonary side effects of the novel neuromuscular-blocking drug CW002 in man. Anesthesiology. 2016;125:1136–1143.
   PubMed Web of Science ®Google Scholar
• Sunaga H, Savarese JJ, McGilvra JD, et al. Preclinical pharmacology of CW002: a nondepolarizing neuromuscular blocking drug of intermediate duration, degraded and antagonized by l-cysteine-additional studies of safety and efficacy in the anesthetized rhesus monkey and cat. Anesthesiology. 2016;125:732–743.
   PubMed Web of Science ®Google Scholar
• National institute of drug abuse. Nationwide Trends. [Revised 2015 Jun]. Available from: https://www.drugabuse.gov/publications/drugfacts/nationwide-trends
   Google Scholar
• Kunins HV. Abuse-deterrent opioid formulations: part of a public health strategy to reverse the opioid epidemic. JAMA Intern Med. 2015;175:987–988.
   PubMed Web of Science ®Google Scholar
• Abramowicz M (ed). From the Medical Letter on Drugs and Therapeutics: Abuse-deterrent opioid formulations. JAMA. 2015; 314:1744–1745.
   PubMed Web of Science ®Google Scholar
• Bartholomaeus JH, Arkenau-Marić E, Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv. 2012;9:879–889.
   PubMed Web of Science ®Google Scholar
• Gudin J, Levy-Cooperman N, Kopecky EA, et al. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med. 2015;16:2142–2151.
   PubMed Web of Science ®Google Scholar
• Fleming AB, Carlson DR, Varanasi RK, et al. Evaluation of an extended-release, abuse-deterrent, microsphere-in-capsule analgesic for the management of patients with chronic pain with dysphagia (CPD). Pain Pract. 2016;16:334–344.
   PubMed Web of Science ®Google Scholar
• Katz N, Kopecky EA, OʼConnor M, et al. A phase 3, multicenter, randomized, double-blind, placebo-controlled, safety, tolerability, and efficacy study of Xtampza ER in patients with moderate-to-severe chronic low back pain. Pain. 2015;156:2458–2467.
   PubMed Web of Science ®Google Scholar
• Pflomm JM (ed). Extended-release hydrocodone (Hysingla ER) for pain. Med Lett Drugs Ther. 2015;57:71–72.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Hydrocodone Bitartrate ER (Hysingla® ER): a review in chronic pain. Clin Drug Investig. 2016;36:969–980.
   PubMed Web of Science ®Google Scholar
• Khan MF, Gharibo C. Abuse deterrent opioids. Tech Reg Anesth Pain Manag. 2010;14:99–103.
   Google Scholar
• Johnson FK, Stark JG, Bieberdorf FA, et al. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. Clin Ther. 2010;32:1149–1164.
   PubMed Web of Science ®Google Scholar
• Johnson F, Setnik B. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability. Pain Physician. 2011;14:391–406.
   PubMed Web of Science ®Google Scholar
• Ruan X, Chen T, Gudin J, et al. Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag. 2010;6:300–303.
   PubMedGoogle Scholar
• Katz N, Sun S, Fow L, et al. Efficacy and safety evaluation of an extended-release morphine sulfate formulation with sequestered naltrexone for the treatment of osteoarthritis. J Pain. 2008;9:41.
   Google Scholar
• Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14:1122–1130.
   PubMed Web of Science ®Google Scholar
• Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14:351–358.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Bruno R, Ali R, et al. The introduction of a potentially abuse deterrent oxycodone formulation: early findings from the Australian national opioid medications abuse deterrence (NOMAD) study. Drug Alcohol Depend. 2015;151:56–67.
   PubMed Web of Science ®Google Scholar
• Coplan PM, Chilcoat HD, Butler SF, et al. The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clin Pharmacol Ther. 2016;100:275–286.
   PubMed Web of Science ®Google Scholar
• Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia. 1999;54:861–867.
   PubMed Web of Science ®Google Scholar
• Bruder EA, Ball IM, Ridi S, et al. Single induction dose of etomidate versus other induction agents for endotracheal intubation in critically ill patients. Cochrane Database Syst Rev. 2015 Jan 8;1:CD010225.
   PubMed Web of Science ®Google Scholar
• Pejo E, Zhou XJ, Shaukat Husain S, et al. Sedative-hypnotic binding to 11β-hydroxylase. Anesthesiology. 2016;125:943–951.
   PubMed Web of Science ®Google Scholar
• de Jong FH, Mallios C, Jansen C, et al. Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab. 1984;59:1143–1147.
   PubMed Web of Science ®Google Scholar
• Pejo E, Cotten JF, Kelly EW, et al. In vivo and in vitro pharmacological studies of methoxycarbonyl-carboetomidate. Anesth Analg. 2012;115:297–304.
   PubMed Web of Science ®Google Scholar